Blog - Page 2 of 5091 - QualityStocks

MondayNov 27, 2023 12:36 pm

QualityStocksNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has closed its previously announced public offering. The offering was comprised of 5,384,615 shares of common stock (or common stock equivalents in lieu thereof) and warrants; the shares were offered at $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants also had an exercise price of $1.30 per share, as well as being exercisable immediately upon issuance; the warrants will expire five years after the initial exercise date. The company noted that total gross proceeds for the…

MondayNov 27, 2023 10:30 am

SOHM Inc. (SHMN) Is ‘One to Watch’

In August 2023, SOHM signed an LOI with CGA Intellectual Holdings Inc. to acquire disruptive stem cell technology and patents The company announced in July 2023 it had closed on the needed financing for its various ongoing projects SOHM announced in April 2023 it had signed an exclusive distribution agreement for its latest product, the anticonvulsant Levetiracetam The company in March 2023 introduced its new topical skincare line of products SOHM (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills,…

MondayNov 27, 2023 9:45 am

D-Wave Quantum Inc. (NYSE: QBTS) Announces Third-Quarter Financial Highlights, Voices Support for Expanded National Quantum Initiative

D-Wave third-quarter revenue grew by 51% year-over-year D-Wave’s third quarter bookings increased by 53% year-over-year, representing the company’s sixth consecutive quarter of year-over-year booking growth, while the first three quarters bookings increased by 125% when compared to the year earlier period CEO Dr. Alan Baratz recently met with Members of Congress to urge them to support the reauthorization of the National Quantum Initiative and ensure that it was expanded to encompass all quantum computing technologies D-Wave Quantum (NYSE: QBTS), a leader in commercial quantum computing systems, software, and services, recently announced financial results for its fiscal third quarter, which ended…

MondayNov 27, 2023 9:00 am

Software Effective Solutions Corp. (SFWJ) Is ‘One to Watch’

MedCana announced in May 2023 full-scale production of non-THC cannabis for export to Europe The company earlier in 2023 commenced construction of crop production infrastructure at sites in Central and South America MedCana has engaged in talks with the government of Argentina about starting production in that country The company in 2023 acquired the assets of Tokan Corp., including an ERP software platform for the cannabis industry Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company…

WednesdayNov 22, 2023 3:21 pm

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk about the company and its achievements and potential. Specifically, the two talked about the company’s recent signing of a definitive agreement to merge with GEDiCube, a United-Kingdom-based medical artificial intelligence (“AI”) company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. During the interview, Dybul discussed the plan to rebrand GEDiCube…

WednesdayNov 22, 2023 2:55 pm

QualityStocksNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Issues Warning to Shareholders

Safety Shot (NASDAQ: SHOT) today announced that it has come to its attention that there are several disclosed short sellers publishing malicious defamatory, inaccurate articles about Safety Shot and its management in a willful attempt to scare SHOT investors out of their positions in hopes of getting them to sell their shares so they can then buy at a lower cost to cover their disclosed short position. According to the announcement, several groups are currently being sued in federal court for publishing these fraudulent articles on other companies, and Safety Shot will be preparing a similar lawsuit against these Cayman…

WednesdayNov 22, 2023 1:32 pm

QualityStocksNewsBreaks – Electronic Servitor Publication Network Inc. (XESP) Helping Modern Businesses Navigate Ever-Evolving Digital Space

Electronic Servitor Publication Network (OTC: XESP), focused on disrupting the market for B2B companies by driving better digital interactions and results, has identified the inefficiencies of simple omnichannel and trendy guerilla marketing strategies, noting their inability to generate enough traction and noise within digitally connected communities. “On its part, Electronic Servitor Publication Network has embraced the challenge and is out to fill the market gap and effectively meet the demand for more. The company focuses on eliminating wastefulness, driving growth and spawning modern businesses that can navigate the ever-evolving digital space, thus increasing digital interactions with new and existing communities.…

WednesdayNov 22, 2023 1:15 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluating Berubicin. According to the announcement, the data showed the comparability of the patient demographics in the two arms of the study, and of the safety data for each therapeutic modality in treating recurrent Glioblastoma Multiforme (“GBM”). The data was presented in a poster presentation at the 28th annual Society of NeuroOncology meeting, which was held Nov. 15–19, 2023, in Vancouver,…

WednesdayNov 22, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer

Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial Genprex took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted event, a Virtual Key Opinion Leaders on Bringing Gene Therapy to the Fight Against Lung Cancers Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was…

WednesdayNov 22, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs

Clene is focused on developing and commercializing novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics The company utilizes an electro-crystallization nanotherapeutics platform, which results in nanocrystals that exhibit catalytic activities multiple times higher than numerous other commercially available nanoparticles that the company has comparatively evaluated Clene is focusing on central nervous system (“CNS”) disorders like amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”) Its lead investigational product, CNM-Au8(R), has so far demonstrated a good safety and tolerability profile, with Phase 2 trials suggesting efficacy in ALS patients Nanotechnology has attracted a great deal of the scientific community’s attention thanks to…

Site Search

Company Search